专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006067633A2 CONJUGATION PRODUCT 审中-公开
标题翻译：联合产品
公开(公告)号：WO2006067633A2
公开(公告)日：2006-06-29
申请号：PCT/IB2005/004058
申请日：2005-12-21
申请人： MOLMED SPA , FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR , CORTI, Angelo , CURNIS, Flavio
发明人： CORTI, Angelo , CURNIS, Flavio
CPC分类号： C07K14/78 , A61K47/64
摘要： A peptide which selectively inhibits α v β 3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.
摘要翻译：一种肽，其选择性地抑制包含NGR基序的肽的脱酰氨基化产物的3'，3'整联蛋白。

2. 发明申请

WO2003020301A1 CHROMOGRANIN A AND FRAGMENTS THEREOF FOR THE TREATMENT OF DISEASES INVOLVING INCREASED VASCULAR PERMEABILITY 审中-公开
标题翻译：用于治疗涉及增加血管渗透性的疾病的色胺A及其片段
公开(公告)号：WO2003020301A1
公开(公告)日：2003-03-13
申请号：PCT/EP2002/008749
申请日：2002-08-06
申请人： FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR , CORTI, Angelo , FERRERO, Elisabetta
发明人： CORTI, Angelo , FERRERO, Elisabetta
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/08
摘要： The use of chromogranin A or fragments thereof for the treatment of diseases related to vascular leakage, such as shock, acute ancute and chronic inflammatory diseases, edema, particulary pulmonary edema, rheumatiod arthritis, congestive heart failure, left ventricular dysfunction and related tissue damages, is herein described.
摘要翻译：嗜铬粒蛋白A或其片段用于治疗与血管渗漏相关的疾病如休克，急性和慢性炎性疾病，水肿，特异性肺水肿，风湿性关节炎，充血性心力衰竭，左心室功能障碍和相关组织损伤，在此描述。

3. 发明申请

WO2010150082A2 USE OF CHROMOGRANIN A AND OF PEPTIDIC DERIVATIVES THEREOF IN THE TREATMENT OF INFLAMMATION 审中-公开
标题翻译：在治疗感染中使用色氨酸A及其衍生物的用途
公开(公告)号：WO2010150082A2
公开(公告)日：2010-12-29
申请号：PCT/IB2010/001522
申请日：2010-06-24
申请人： UNIVERSITA' DEGLI STUDI DI MILANO , FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR , MARCUCCI, Fabrizio , CORTI, Angelo , COLOMBO, Barbara , GASPARRI, Anna, Maria , RUMIO, Cristiano , PALAZZO, Marco , ZANOBBIO, Laura
发明人： MARCUCCI, Fabrizio , CORTI, Angelo , COLOMBO, Barbara , GASPARRI, Anna, Maria , RUMIO, Cristiano , PALAZZO, Marco , ZANOBBIO, Laura
IPC分类号： A61K38/17
CPC分类号： C07K14/575 , A61K38/00
摘要： The invention concerns the use of chromogranin A, its peptidic derivatives and their non-peptidic peptidomimetic derivatives in the treatment and prevention of inflammatory pathologies of the digestive system, in the treatment and/or prevention of diseases such as Crohn's disease, ulcerative colitis and, more generally, chronic bowel disease and inflammatory diseases of the respiratory system.
摘要翻译：本发明涉及嗜铬粒蛋白A，其肽衍生物及其非肽肽模拟衍生物在治疗和预防消化系统的炎性病理学中的用途，用于治疗和/或预防诸如克罗恩病，溃疡性结肠炎和/ 更一般地，慢性肠病和炎性疾病的呼吸系统。

4. 发明申请

WO2004105782A2 TUMOR-TARGETED DRUG DELIVERY SYSTEMS AND USES THEREOF 审中-公开
标题翻译：肿瘤靶向药物输送系统及其用途
公开(公告)号：WO2004105782A2
公开(公告)日：2004-12-09
申请号：PCT/EP2004/005677
申请日：2004-05-26
申请人： G. GASLINI CHILDREN'S HOSPITAL , THE GOVERNORS OF THE UNIVERSITY OF ALBERTA , FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR , PONZONI, Mirco , CORTI, Angelo , ALLEN, Theresa, M.
发明人： PONZONI, Mirco , CORTI, Angelo , ALLEN, Theresa, M.
IPC分类号： A61K38/00
CPC分类号： A61K38/10 , A61K9/127 , A61K31/00 , A61K31/704 , A61K38/08
摘要： The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.
摘要翻译：本发明涉及用于将治疗剂递送至肿瘤的靶向递送系统。本发明还涉及通过杀死肿瘤细胞和肿瘤相关内皮细胞将治疗剂递送至肿瘤以预防和治疗癌症的方法。特别地，本发明提供了一种肿瘤靶向药物递送系统，其包含与包封治疗剂，优选药物例如细胞毒剂或化学治疗剂的递送载体连接的含NGR分子。具体地说，与其他递送系统相比，本发明的递送系统能够将更多量的治疗剂递送到肿瘤。特别地，本发明的递送系统能够在肿瘤或肿瘤细胞或肿瘤支持细胞附近积聚更多量的治疗剂，导致肿瘤细胞和肿瘤相关的内皮细胞的暴露与其他递送系统相比，治疗剂量更长的时间。本发明还描述了包含本发明的递送系统的药物组合物。本发明还涉及一种肿瘤治疗，其包括与其它递送系统相比，本发明的系统递送的治疗剂的量增加。递送系统和药物组合物可以与其他预防或治疗剂和/或抗癌治疗单独或组合地依次或同时地施用于受试者，优选人。

5. 发明申请

WO2004041297A2 MODIFIED CYTOKINES FOR USE IN CANCER THERAPY 审中-公开
标题翻译：修饰的细胞因子用于癌症治疗
公开(公告)号：WO2004041297A2
公开(公告)日：2004-05-21
申请号：PCT/IB2003/005657
申请日：2003-11-05
申请人： FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR , CORTI, Angelo
发明人： CORTI, Angelo
IPC分类号： A61K38/00
CPC分类号： C07K7/08 , A61K31/70 , A61K38/191 , A61K47/6425 , A61K47/6849 , A61K2039/505 , C07K5/0819 , C07K5/1021 , C07K7/06 , C07K14/525 , C07K14/555 , C07K14/57 , C07K16/30 , C07K2319/00 , A61K2300/00
摘要： Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
摘要翻译：能够使肿瘤血管和抗原呈递细胞归巢的细胞因子衍生物及其作为抗肿瘤剂的用途。

6. 发明申请

WO2003093478A1 IMMUNOCONJUGATES FOR THE TREATMENT OF TUMOURS 审中-公开
标题翻译：用于治疗肿瘤的免疫球蛋白
公开(公告)号：WO2003093478A1
公开(公告)日：2003-11-13
申请号：PCT/IB2003/002187
申请日：2003-04-30
申请人： MOLMED SPA , CORTI, Angelo , CURNIS, Flavio
发明人： CORTI, Angelo , CURNIS, Flavio
IPC分类号： C12N15/62
CPC分类号： A61K49/0008 , A61K38/191 , A61K47/64 , A61K47/642 , A61K47/6813 , A61K47/6851 , A61K47/6887 , A61K51/0495 , C07K14/525 , C07K14/57 , C07K2319/01
摘要： A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
摘要翻译：一种药物组合物，其包含细胞因子和肿瘤靶向部分（TTM）的缀合物和药学上可接受的赋形剂，其中所述细胞因子以不引起负反馈机制的量存在。

7. 发明申请

WO2003092737A1 FUSIONS OF CYTOKINES AND TUMOR TARGETING PROTEINS 审中-公开
标题翻译：细胞因子和肿瘤靶向蛋白的融合
公开(公告)号：WO2003092737A1
公开(公告)日：2003-11-13
申请号：PCT/IB2003/002515
申请日：2003-04-30
申请人： MOLMED SpA , CORTI, Angelo , CURNIS, Flavio
发明人： CORTI, Angelo , CURNIS, Flavio
IPC分类号： A61K47/48
CPC分类号： C07K14/57 , A61K38/00 , A61K47/64 , A61K47/6801 , C07K14/52 , C07K14/525 , C07K2319/00
摘要： A conjugate of a cytokine and a tumor targeting moiety (TTM) with the provisos that when cytokine is TNF-α, TNF-β or IFN-γ, the TTM is other than a CD13 ligant; when the cytokine is IL-12, the TTM is other than an antiboy to fibronectin; when the cytokine is TNF, the TTM is other than an antibody to the transferrin receptor; and when the cytokine is TNF, IFN-γ or IL-2 the antibody is other than an antibody to the TAG72 antigen.
摘要翻译：细胞因子和肿瘤靶向部分（TTM）的缀合物，条件是当细胞因子是TNF-α，TNF-β或IFN-γ时，TTM不是CD13连接酶; 当细胞因子是IL-12时，TTM不是纤连蛋白的抗体; 当细胞因子是TNF时，TTM不是转铁蛋白受体的抗体; 当细胞因子是TNF，IFN-γ或IL-2时，该抗体不是对TAG72抗原的抗体。

8. 发明申请

WO2013140317A2 PEPTIDES 审中-公开
标题翻译：肽
公开(公告)号：WO2013140317A2
公开(公告)日：2013-09-26
申请号：PCT/IB2013/052040
申请日：2013-03-14
申请人： OSPEDALE SAN RAFFAELE SRL , CORTI, Angelo , CURNIS, Flavio
发明人： CORTI, Angelo , CURNIS, Flavio
IPC分类号： A61K47/48
CPC分类号： A61K47/48284 , A61K31/337 , A61K38/191 , A61K38/208 , A61K47/48015 , A61K47/48238 , A61K47/52 , A61K47/62 , A61K47/643 , A61K49/0056 , A61K49/0093 , C07K7/64 , C07K2319/31 , C07K2319/33 , C07K2319/74
摘要： A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
摘要翻译：一种包含肽的产物，其包含选自isoDGR，NGR和DGR的基序，其中所述肽通过连接其主链的N-和C-末端而环化，并且其中所述环肽与白蛋白结合。

9. 发明申请

WO2008152508A3 CYTOKINE CONJUGATE 审中-公开
公开(公告)号：WO2008152508A3
公开(公告)日：2008-12-18
申请号：PCT/IB2008/002021
申请日：2008-05-07
申请人： MOLMED SPA , TRAVERSARI, Catia , VALENTINIS, Barbara , TANZARELLA, Sylvia , CORTI, Angelo , MARTUCCI, Anna Maria , TOMA, Caterina
发明人： TRAVERSARI, Catia , VALENTINIS, Barbara , TANZARELLA, Sylvia , CORTI, Angelo
IPC分类号： A61K47/48 , A61P35/00
摘要： An IL12 heterodimer comprising a p35 subunit and a p40 subunit wherein the p40 subunit is conjugated to a first peptide containing the NGR, DGR or isoDGR motif and the p35 subunit is optionally conjugated to a second peptide containing the NGR, DGR or isoDGR motif and wherein the sequence of the first peptide and the sequence of the second peptide may be the same or different.

10. 发明申请

WO2008068621A2 COMBINATION PRODUCT 审中-公开
标题翻译：组合产品
公开(公告)号：WO2008068621A2
公开(公告)日：2008-06-12
申请号：PCT/IB2007/004299
申请日：2007-12-05
申请人： MOLMED SPA , CORTI, Angelo
发明人： CORTI, Angelo
IPC分类号： A61K45/06 , A61K31/405 , A61K38/21 , A61K35/00
CPC分类号： A61K31/405 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical product comprising, in combination, (i) an indoleamine 2,3- dioxygenase (IDO) inhibitor and (ii) a conjugation product of IFNγ and a targeting moiety (TM)or a polynucleotide encoding therefor.
摘要翻译：一种药物产品，其组合包含（i）吲哚胺-2,3-双加氧酶（IDO）抑制剂和（ii）IFNγ的缀合产物和靶向部分（TM）或其编码的多核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式